J. Lewis

发表

Gene Expression: Human Cells

Gene Lee, J. Chon, M. Cacciuttolo, 2009 .

Hepatitis A Vaccines

J. Lewis, 1999 .

Quantifying the titer and quality of adenovirus stocks.

B. Mathis, J. Wolf, J. Lewis, 2008, Methods in molecular biology.

Development and application of a quantitative RT-PCR potency assay for a pentavalent rotavirus vaccine (RotaTeq).

R. Sitrin, T. Ranheim, J. Hennessey, 2006, Journal of virological methods.

Phosphatase Reverses Stat 1 Activation Signal Transduction : Viral VH 1 Vaccinia Virus Blocks Gamma Interferon

P. Najarro, J. Lewis, P. Traktman, 2001 .

Vaccinia Virus Blocks Gamma Interferon Signal Transduction: Viral VH1 Phosphatase Reverses Stat1 Activation

P. Najarro, J. Lewis, P. Traktman, 2001, Journal of Virology.

Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine

E. Wimmer, H. Schuitemaker, J. Cello, 2016, PLoS pathogens.

Acute interstitial nephritis associated with cephapirin

J. Lewis, Joseph P. Rindone, 1987, Drug intelligence & clinical pharmacy.

Thymidine kinase genes and the induction of anti‐rival responses by interferon

J. Lewis, M. Esteban, J. Lewis, 1983, FEBS letters.

PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine.

H. Schuitemaker, V. Klaren, J. Custers, 2013, Vaccine.

Using QPCR to assign infectious potencies to adenovirus based vaccines and vectors for gene therapy: toward a universal method for the facile quantitation of virus and vector potency.

Charles Y. Tan, B. Mathis, J. Wolf, 2005, Vaccine.

Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunization with immune globulin.

D. Nalin, S. Lemon, J. Davide, 1997, The Journal of infectious diseases.

Anatomy of a trial: a historical view of the Monroe inactivated hepatitis A protective efficacy trial.

B. Wiens, D. Nalin, R. Sitrin, 1993, Journal of hepatology.

Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview.

B. Wiens, D. Nalin, E. Ellerbeck, 1993, Journal of hepatology.

Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds

D. Hazuda, W. Mcclements, J. Tomassini, 1994, Antimicrobial Agents and Chemotherapy.

Development of the formalin-inactivated hepatitis A vaccine, VAQTA from the live attenuated virus strain CR326F.

R. D. Keys, J. Davide, J. Lewis, 1993, Journal of hepatology.

Identification and characterization of mycobacteriophage L5 excisionase

G. Hatfull, G F Hatfull, J A Lewis, 2000, Molecular microbiology.

Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees

S. Matsushita, W. Schleif, E. Emini, 1990, Journal of virology.